Clinical trials: Overt Hepatic Encephalopathy
Overt Hepatic Encephalopathy
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but…
- Trial name
- NCT06483737
- Testing
- Human albumin infusion at a modified dosage, Human albumin infusion at a routine dosage, Lactulose
- Where
- China
- Volunteers
- 174 people
- Sponsor
- General Hospital of Shenyang Military Region
Overt Hepatic Encephalopathy
A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.
The goal of this trial is to learn if drugs in group A, B, C and D works to treat reversal of grades in people with overt hepatic encephalopathy. It will also provide information regarding safety of drugs in group A, B, C and D.
- Trial name
- ARGO-HEC (NCT07037394)
- Testing
- Probiotic plus lactulose, Rifaximin plus lactulose, L-ornithine-L-aspartate plus latulose
- Where
- Pakistan
- Volunteers
- 252 people
- Sponsor
- Qurratul Ain Jamil
Hepatic Encephalopathy, Minimal Hepatic Encephalopathy
A Study of MHE in Patients With Liver Diseases
The study analyzes the diagnostic efficacy of neurophysiological tests and blood biomarkers on MHE, predicts risk factors on the development of OHE and investigate the mortality of MHE in patients with cirrhosis and acute on…
- Conditions
- Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Overt Hepatic Encephalopathy
- Trial name
- NCT04058327
- Testing
- neurophysiological tests, blood biomarkers.
- Where
- China
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Qin Ning
Decompensated Cirrhosis, CMV Reactivation
Prospective Cohort Study of Complications and Outcomes in Cirrhosis
This is a multi-center, nested cohort study intended to investigate the prevalence, risk factors, and outcomes of complications in patients with acutely decompensated cirrhosis, especially focused on Cytomegalovirus (CMV)…
- Conditions
- Decompensated Cirrhosis, CMV Reactivation, Overt Hepatic Encephalopathy
- Trial name
- NCT06374511
- Testing
- Test for CMV reactivation
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Overt Hepatic Encephalopathy
Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).
- Trial name
- OHE (NCT03515044)
- Testing
- 40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily
- Where
- 34 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.
- Trial name
- STOP-HE (NCT01966419)
- Testing
- ornithine phenylacetate
- Where
- 131 sites in United States, Australia and 15 more
- Volunteers
- 231 people
- Sponsor
- Ocera Therapeutics, Inc.